Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DDX52 is a member of the DEAD-box family of RNA helicases, characterized by two conserved domains responsible for ATP binding and RNA remodeling activities. It plays a fundamental role in ribosome biogenesis by promoting the processing and maturation of precursor rRNA, particularly the 47S pre-rRNA, leading to protein synthesis and cell growth. DDX52 is rapidly upregulated during wound healing and tissue regeneration in vertebrates and is essential for post-embryonic development and organ growth. Deficiency or suppression of DDX52 results in stunted growth and defective regeneration, while its overexpression can promote growth in early developmental stages. Human DDX52 is associated with several diseases, and the DEAD-box helicase family, in general, is linked to cancer and viral replication, highlighting their potential as therapeutic targets.
Not established for direct inhibitors. General mechanism involves inhibition of rRNA synthesis and RNA transcription (as seen with Actinomycin D, which inhibits RNA polymerase I and thus rRNA synthesis)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Probable ATP-dependent RNA helicase DExD-box helicase 52 (DDX52).